UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

[ X ]             QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2001

                                       OR

[   ]             TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission file number: 0-18271


                             BIOMERIDIAN CORPORATION
                           ---------------------------
             (Exact name of registrant as specified in its charter)


           Utah                                          87-0467614
          ------                                         ----------
  (State or other jurisdiction                          (I.R.S. Employer
of incorporation or organization)                      Identification No.)


                12411 South 265 West, Suite F, Draper, Utah 84020
               ---------------------------------------------------
                    (Address of principal executive offices)
                                   (Zip Code)

                                 (801) 501-7517
                                 ---------------
              (Registrant's telephone number, including area code)


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X No _____

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date:

Number of shares outstanding at March 31, 2001: 30,660,331 shares
Class:  Common Stock, $.0002 par value

Transitional Small Business Disclosure Format:  Yes _____   No __X___



<PAGE>


                                   FORM 10-QSB

                       Financial Statements and Schedules
                             BioMeridian Corporation

                      For the Quarter Ended March 31, 2001

The  following  financial  statements  and schedules of the  registrant  and its
consolidated subsidiaries are submitted herewith:


                         PART I - FINANCIAL INFORMATION
                        --------------------------------
Item 1.  Financial Statements

         Condensed consolidated balance sheet for March 31, 2001              3

         Condensed consolidated statement of operations for
         the three months ended March 31, 2001 and 2000                       4

         Condensed statement of cash flows for the three
         months ended March 31, 2001 and 2000                                 5

         Notes to condensed consolidated financial statements                 7

Item 2.  Management's Discussion and Analysis of Financial
         Condition and Results of Operations                                  8


                           PART II - OTHER INFORMATION
                          -----------------------------
Item 1.  Legal Proceedings                                                   10

Item 2.  Changes in Securities                                               10

Item 3.  Defaults upon Senior Securities                                     10

Item 4.  Submission of Matters to a Vote of Security Holders                 10

Item 5.  Other information                                                   10

Item 6(a)         Exhibits                                                   10

Item 6(b)         Reports on Form 8-K                                        10


                                       2
<PAGE>

                           BIOMERIDIAN CORPORATION
                              AND SUBSIDIARIES

                    Condensed Consolidated Balance Sheet


                                                                     31-Mar-01
                                   ASSETS                           (Unaudited)
                                                                    -----------
Current Assets:
 Accounts Receivable                                               $    835,681
 Investment in Securities                                             1,200,000
 Inventories                                                            152,997
 Prepaid Expenses                                                        10,825
 Other Current Assets                                                    26,813
                                                                   ------------
   Current Assets                                                     2,226,316
                                                                   ------------

 Property and Equipment, net                                            191,548
 Goodwill, net                                                          107,699
 Licenses & Technology, net                                              89,655
                                                                   ------------
   Total Assets                                                    $  2,615,218
                                                                   ============
                                 LIABILITIES

Current Liabilities:
 Cash Overdraft                                                    $     67,591
 Accounts Payable                                                       311,275
 Accrued Personnel Costs                                                 98,857
 Accrued Liabilities                                                    175,211
 Accrued Interest Payable                                               205,752
 Related Party Notes Payable                                            660,149
 Notes Payable                                                          151,826
 Current Portion of long-term debt                                      301,581
                                                                   ------------
   Current Liabilities                                                1,972,242

 Related Party Long-Term Debt                                           697,899
 Long-Term Debt                                                         962,374
                                                                   ------------
   Total Liabilities                                                  3,632,515
                                                                   ------------
                            STOCKHOLDERS' DEFICIT

 Common Stock, par value $.0002 per share;
   50,000,000 shares authorized, 30,660,331 shares
   issued and outstanding                                                 6,132
 Additional Paid-in Capital                                          15,385,709
 Accumulated Deficit                                                (16,409,138)
                                                                   ------------
   Total Stockholders' Deficit                                       (1,017,297)
                                                                   ------------
     Total Liabilities and Stockholders' Deficit                   $  2,615,218
                                                                   ============

                                       3
<PAGE>
                                BIOMERIDIAN CORPORATION
                                   AND SUBSIDIARIES

                    Condensed Consolidated Statement of Operations
                                      (Unaudited)

                                                Three Months        Three Months
                                                  Ended                 Ended
                                                 31-Mar-01            31-Mar-00
                                                ------------        ------------
 Net Sales                                        $1,383,833        $ 1,793,945
 Cost of Sales                                       244,393            268,855
                                                ------------        -----------
   Gross Margin                                    1,139,440          1,525,090

 Variable Selling Costs                              174,739            243,232
                                                ------------        ------------
   Contribution Margin                               964,701          1,281,858

Operating Expenses:
 Administration & Finance                            529,409            344,979
 Depreciation and Amortization                        45,315            171,347
 Customer Support                                     42,898             37,235
 Engineering & Development                            98,811             72,458
 Marketing                                           105,702             76,055
 Quality & Assurance                                  36,020             36,231
 Sales - Domestic                                    237,321            198,163
 Sales - International                                31,718             67,326
 Training & Education                                146,725            128,950
                                                ------------        -----------
    Total Operating Expenses                       1,273,919          1,132,744
                                                ------------        -----------
 Income/(Loss) from Operations:                     (309,218)           149,114

Other Income/(Expense):
 Other Income/(Expense):                             (11,000)            13,866
 Gain on Settlements                                  40,094                 -
 Gain on Sale of Bio-Origins                         474,069                 -
 Interest Expense                                    (85,228)          (123,392)
                                                ------------        -----------
                                                     417,935           (109,526)
                                                ------------        -----------
    Income before income taxes                       108,716             39,588
    Provision for income taxes                            -                  -
                                                ------------        ------------
    Net Income                                  $    108,716        $    39,588
                                                ============        ===========

 Net Income per share - basic and diluted               0.00               0.00
                                                ============        ===========

 Weighted average shares outstanding -
    basic and diluted                             30,660,331         27,474,997
                                                ============        ============

                                       4
<PAGE>
                             BIOMERIDIAN CORPORATION
                                AND SUBSIDIARIES

                 Condensed Consolidated Statement of Cash Flows
                                   (Unaudited)

<TABLE>
<CAPTION>

                                                                          Three Months      Three Months
                                                                             Ended               Ended
                                                                           31-Mar-01         31-Mar-00
                                                                          -------------     -------------
<S>                                                                       <C>                <C>
Cash Flows from Operating Activities:
 Net Income                                                               $   108,717        $    39,588
 Adjustments to Reconcile Net Income
   to Net Cash (used in) provided by Operating Activities:
     Provision for Bad Debt                                                    77,479             10,000
     Gain on Settlements                                                      (40,094)                 -
     Depreciation and Amortization Expense                                     45,315            171,347
     (Gain)/Loss on sale of Bio-Origins                                      (474,069)                 -
 (Increase)/Decrease in:
   Accounts Receivable                                                        154,588           (375,365)
   Notes Receivable                                                                              774,921
   Inventory                                                                   (5,987)            45,355
   Prepaid Expenses                                                                 -            (16,752)
   Other Current Assets                                                        (5,500)           (13,300)
 Increase/(Decrease) in:
   Accounts Payable                                                          (151,500)          (224,346)
   Accrued Liabilities                                                         24,658             25,979
                                                                          -----------        -----------
 Net Cash Provided by/(Used in) Operating Activities                         (266,393)           437,427
                                                                          -----------        -----------
Cash Flows from Investing Activities:
 Purchase of Property & Equipment                                              (3,252)           (16,965)
 Proceeds from Sale of Bio-Origins                                            200,000                  -
                                                                          -----------        -----------
 Net Cash Provided by/(Used in) Investing Activities                          196,748            (16,965)
                                                                          -----------        -----------
Cash Flows from Financing Activities:
 Proceeds from cash over-draft                                                 67,591
 Proceeds from Related Party Notes                                            100,000            490,000
 Principal Payments on Related Party Notes                                          -           (212,000)
 Principal Payments on Notes Payable                                         (115,000)          (945,150)
 Principal Payments on Long-term Debt                                         (70,681)              (926)
                                                                          -----------        -----------
 Net Cash Used in Financing Activities:                                       (18,090)          (668,076)
                                                                          -----------        -----------
 Net Decrease in cash                                                         (87,735)          (247,614)

 Cash, Beginning of Period                                                     87,735            280,199
                                                                          -----------        -----------
 Cash, End of Period                                                      $         0        $    32,585
                                                                          ===========        ===========

</TABLE>


                                       5
<PAGE>


                             BIOMERIDIAN CORPORATION
                                AND SUBSIDIARIES

                 Condensed Consolidated Statement of Cash Flows
                                   (Unaudited)


                                                    Three Months    Three Months
                                                       Ended           Ended
                                                     31-Mar-01       31-Mar-00
Cash paid during the period for:                    ------------    ------------

 Interest                                           $    47,916     $   148,325
                                                    ===========     ===========

 Income Taxes                                       $         -     $         -
                                                    ===========     ===========

Non-cash Financing and Investing Activities:

         During the three months ended March 31, 2001, the Company reduced notes
payable by $6,000 and accounts payable by $34,094. The Company recognized a gain
on settlement in the amount of $40,094.

         During  the  three  months  ended  March 31,  2001,  the  Company  sold
Bio-Origins,  Inc. to the  Chairman  of the  Board/CEO  and a limited  liability
company  owned by him.  The  purchaser  paid the  Company  $200,000  in cash and
assumed $250,000 of liabilities  under two promissory notes made by the Company.
The  purchaser  also assumed  accrued  liabilities  of $23,750,  trade  payables
totaling  $3,259,  and acquired  property and equipment with a net book value of
$2,940.

         During the three  months ended March 31,  2000,  the Company  converted
accrued  interest payable to a shareholder and director to a note payable in the
amount of $98,048.




                                       6

<PAGE>


                             BIOMERIDIAN CORPORATION
                                AND SUBSIDIARIES

              Notes to Condensed Consolidated Financial Statements

1.       The unaudited condensed  consolidated  financial statements include the
         accounts of  BioMeridian  Corporation.  (The  "Company") and its wholly
         owned subsidiaries, BioMeridian International, Inc. ("BioMeridian") and
         Bio-Origins, Inc. ("Bio-Origins").

2.       The unaudited condensed  consolidated  financial statements include all
         adjustments,  consisting of normal recurring  items,  which are, in the
         opinion  of  management,  necessary  to present  fairly  the  financial
         position  of the  Company  as of  March  31,  2001 and the  results  of
         operations  for the three months ended March 31, 2001 and 2000 and cash
         flows for the three months  ended March 31, 2001 and 2000.  The results
         of  operations  for the  three  months  ended  March  31,  2001 are not
         necessarily  indicative  of  quarterly  results to be expected  for the
         remainder of the year.

3.       The  amount of the  basic  income  per  share is based on the  weighted
         average  number  of  shares  outstanding  at March  31,  2001 and 2000,
         respectively.  The computation of diluted  earnings per common share is
         based on the weighted average number of shares  outstanding  during the
         year plus common stock  equivalents which would arise from the exercise
         of stock  options and warrants  outstanding  using the  treasury  stock
         method and the average  market price per share during the year.  Common
         stock  equivalents  are not included in the diluted  earnings per share
         calculation when their effect is antidilutive.

4.       As of  December  31,  2000,  the Company  entered  into both a 48-month
         amortizing  term loan and a  revolving  line-of-credit  agreement.  The
         amortizing term loan originated with a principal balance of $1,300,000,
         an interest  rate equal to the prime rate,  plus .5% (8.5% at March 31,
         2001),  and  monthly   principal  and  interest   payments  of  $33,000
         commencing  January 1, 2001. At March 31, 2001,  the Company was not in
         compliance with certain  covenants related to this note.  However,  the
         bank has  agreed to waive the  non-compliance.  The  revolving  line of
         credit was established with a principal borrowing limit of $200,000, an
         interest  rate of prime,  plus .5% (8.5% at March  31,  2001),  monthly
         interest payments  commencing January 1, 2001, and principal payable on
         demand or on  December  1,  2001.  This line of credit has been used to
         fund the  operations  of the Company and as of March 31,  2001,  had an
         outstanding balance of $81,826.

5.       During  the  three  months  ended  March 31,  2001,  the  Company  sold
         substantially  all of the assets of Bio-Origins,  Inc. to the Company's
         Chairman of the Board and Chief  Executive  Officer and an LLC owned by
         him.  The  purchaser  paid the  Company  $200,000  in cash and  assumed
         $250,000 of debt plus accrued  interest under two promissory notes made
         by the Company.  The purchaser  also assumed  accrued  liabilities  and
         trade  payables  totaling  $27,009.  The  acquisition  was  reported in
         Current  Report  on Form 8-K filed  with the  Securities  and  Exchange
         Commission on April 13, 2001.

6.       During the three months ended March 31,  2001,  the Company  borrowed a
         net amount of $100,000 from the Company's Chief Executive Officer.  The
         note payable bore interest at 12% and was  extinguished  as part of the
         sale of the Bio-Origins assets.


                                       7
<PAGE>


                         PART I - FINANCIAL INFORMATION


Item 2.  Management's Discussion and Analysis of Financial Condition and Results
         of Operations

Three-month period ended March 31, 2001 compared to the three-month period ended
March 31, 2000.

The mission of BioMeridian Corporation is to develop and market state-of-the-art
methods for delivering  integrative  healthcare to the marketplace.  BioMeridian
manufactures and sells the MSA/IMAG and BEST systems to healthcare practitioners
throughout  the  world.  This  equipment  is used to assess  stress  and  assist
healthcare practitioners in the analysis and treatment of certain conditions. If
stress  or  imbalance  is  detected  in  a  patient,   the  systems  assist  the
practitioner  in  recommending a course of treatment or therapy to alleviate the
stress or to restore balance to the body's meridian  systems.  BioMeridian  also
provides  training  classes and support  services for health care  practitioners
that utilize these systems. The MSA/IMAG system is registered with the U.S. Food
and Drug Administration as a stress-monitoring device.

For the three months ended March 31, 2001,  the Company  achieved sales revenues
of  $1,383,833,  which  resulted in net income of $108,717  compared  with sales
revenues of  $1,793,945,  which  resulted in net income of $39,588 for the three
months ended March 31, 2000. Fifty-seven percent (57%) of this decrease in sales
of $410,112 is  attributable  to a reduced number of BTA units sold in 2001. The
remaining decline is principally attributable to reduced MSA units sold into the
international marketplace.  Contribution margin for the three months ended March
31, 2001 totaled  $964,701 or 70% of sales as compared with $1,281,858 or 71% of
sales for the same period in the prior year.  Operating costs totaled $1,273,919
and operating loss amounted to $309,218  during the three months ended March 31,
2001  compared with  $1,132,744 of operating  expenses and $149,114 of operating
profit during the prior year.  During the three months ended March 31, 2001, the
Company had increased  expenditures  for marketing  and product  development  by
approximately  $56,000 as compared to the same period in the prior year.  Beyond
these  operating  comparisons,  the  improvement  in net income during the three
months  ended March 31, 2001 was due  primarily  to $474,069 in gain booked as a
result of the sale of  substantially  all of the assets of Bio-Origins,  Inc., a
wholly-owned  subsidiary of the Company, to a limited liability company owned by
the  Company's  Chairman  of the Board and Chief  Executive  Officer  and to the
Chairman/CEO personally.

Liquidity and Capital Resources

As of December 31,  2000,  the Company  entered into both a 48-month  amortizing
term loan and a revolving  line-of-credit  agreement.  The amortizing  term loan
originated with a principal balance of $1,300,000, an interest rate equal to the
prime  rate,  plus .5% (8.5% at March  31,  2001),  and  monthly  principal  and
interest payments of $33,000  commencing  January 1, 2001. The revolving line of
credit was established with a principal borrowing limit of $200,000, an interest
rate of prime,  plus .5% (8.5% at March 31,  2001),  monthly  interest  payments
commencing  January 1, 2001,  and principal  payable on demand or on December 1,
2001.  This line of credit has been used to fund the  operations  of the company
and as of March 31, 2001, had an outstanding balance of $81,826.

                                       8
<PAGE>

During the three months ended March 31, 2001, the Company  borrowed a net amount
of $100,000 from the Company's  Chief  Executive  Officer.  The note payable was
extinguished as part of the sale of the Bio-Origins assets.

                                       9
<PAGE>


                           PART II - OTHER INFORMATION

Item 1.  Legal proceedings:

In November 2000, the Company was informed by a letter of a competitors' counsel
that the Company should 'cease and desist' in the production and sale of certain
of its devices.  Believing that the Company has a valid and enforceable  license
to market the devices in question, the Company filed suit against the competitor
on December 5, 2000. The competitor  has responded and filed  counterclaims  and
the process is moving forward without a clear  indication of the outcome at this
time. The Company  believes it possesses a valid right to produce and market the
devices, and intends to aggressively pursue its rights in the litigation.

Item 2.  Changes in Securities:     None.

Item 3.  Defaults upon Senior Securities:   None.

Item 4.  Submission of Matters to a Vote of Security Holders: None.

Item 5.  Other information: None.

Item 6.  Exhibits and Reports on Form 8-K

A  Current  Report  on Form  8-K,  which  reported  the  sale of the  assets  of
Bio-Origins, Inc., was filed on April 13, 2001.

                                       10
<PAGE>


SIGNATURES

1.       In accordance with the requirements of the Exchange Act, the registrant
         caused  this  report  to be signed  on its  behalf by the  undersigned,
         thereunto duly authorized.


2.                                       BIOMERIDIAN CORPORATION
3.                                       -----------------------
4.                                            (Registrant)




5.       \s\William A. Fresh                                      May 15, 2001
6.       ------------------------                                 ------------
7.       William A. Fresh                                             Date
8.       Chairman and Chief Executive Officer


                                       11
<PAGE>